 |
| | Business Summary: Transgenomic, Inc. provides products for the purification and analysis of nucleic acids used in the life sciences industry for research primarily on molecular genetics and diagnostics. | | | Address
12325 Emmet Street
Omaha
, NE 68164
Phone: 402-452-5400
Fax: 402-452-5401
Website: http://www.transgenomic.com
| | | Transfer Agent |
|---|
Wells Fargo Shareowner Services
| Employees: 103
ShareHolders: 2800 | Founded: 1997
Domicile: Delaware | | | |
| | Transgenomic, Inc. provides products for the purification and analysis of nucleic acids used in the life sciences industry for research focused on molecular genetics and diagnostics. It also provides genetic variation analytical services to the medical research, clinical and pharmaceutical markets. Net sales are categorized as Instrument Related Business and Laboratory Services.
The Instrument Related Business comprises bioinstruments, including the company's flagship product, the WAVE System, and bioconsumables. The WAVE System has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. There was a worldwide installed base of over 1,475 WAVE Systems as of Mar. 31, 2010. Transgenomic also distributes bioinstruments produced by other manufacturers through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by technical support personnel.
The installed WAVE base and some third-party installed platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. Transgenomic develops, manufactures and sells these consumable products. In addition, Transgenomic manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of HPLC separation columns.
The company continues to seek emerging markets and novel applications to provide it with new opportunities for its WAVE System such as its newly launched K-RAS mutation detection kit. It also seeks opportunities to diversify into new markets, including the personalized medicine market (particularly in oncology). In addition, Transgenomic also sells refurbished WAVE Systems in order to provide an opportunity for customers that may not be able to afford the cost of a new system.
Located in Omaha, Nebraska, the company's molecular clinical reference laboratory specializes in mitochondrial and molecular diagnostic testing including genetic testing for oncology, hematology and inherited disorders. In addition, pharmacogenomics research services are provided by the company's Contract Research Organization in Omaha, Nebraska. The Contract Research Organization specializes in pharmocogenomic, biomarker and mutation discovery research serving the pharmaceutical and biomedical industries for disease research, drug and diagnostic development and clinical trial support.
The company was founded in 1997 and is based in Omaha, Nebraska. | | History: INCORPORATED in Delaware Mar. 6, 1997. | | | | Subsidiaries: |
|---|
Annovis, Inc.
Transgenomic Japan, Inc.
Transgenomic Limited
| | | | | | Capital Expenditures, thousand. US Dollars |
|---|
| Year | Amount | | 2009 | 351 |
| | | | | | Research and Development Expenditures, thousand. US Dollars |
|---|
| Year | Amount | | 2009 | 3,182 |
| | | | | |
|
Management
|
|---|
| Officers | Position |
|---|
| Rodney Markin | Chairman | | Brett L. Frevert | Chief Financial Officer | | Kim Sutton Golodetz | Investor Relations Contact |
| | Directors |
|---|
| Rodney Markin | | Michael B. McNulty | | Antonius P. Schuh | | Jeffrey L. Sklar | | Greg T. Sloma | | | |
| | | | Capitalization as of 03/31/2010: | | | | | Authorized Shares | Outstanding Shares |
|---|
| Preferred $0.01 par | 15,000,000 | None | | Common $0.01 par | 100,000,000 | 49,189,672 |
| | | | LONG TERM DEBT: None. | | | | Common $0.01 par | | | | COMMON OFFERED: July 18, 2000, the company, through underwriters led by Chase Securities Inc., Bear, Stearns & Co. Inc. and Dain Rauscher Inc., offered 4,480,000 Common shares at $15.00 per share; comm., $1.05 per share. An additional 672,000 were available to cover over-allotments. | | | |
Stockholders:
12/31/2009,
2800.
| | PRINCIPAL STOCKHOLDERS: March 22, 2010, LeRoy C. Kopp owned or controlled 26.0% of the Common, Barclays PLC 9.9%, AMH Equity, LLC 9.9% and Michael A. Roth and Brian J. Stark 6.7%. | | | |
Transfer Agent: Wells Fargo Shareowner Services
South St. Paul
, MN | | | | OTC Bulletin Board( Primary): TBIO | | | | Exchange | Year | High | Low |
|---|
| OTC Bulletin Board | 2009 | 0.7500 | 0.2100 | | OTC Bulletin Board | 2008 | 0.8700 | 0.2400 | | OTC Bulletin Board | 2007 | 42.6900 | 26.5600 | | Nasdaq Capital Market | 2006 | 1.0300 | 0.3100 | | NASDAQ National Market | 2005 | 1.2500 | 0.3800 | | NASDAQ National Market | 2004 | 3.3200 | 1.0000 | | NASDAQ National Market | 2003 | 4.2200 | 0.9300 | | NASDAQ National Market | 2002 | 11.0500 | 1.5100 | | NASDAQ National Market | 2001 | 25.9900 | 5.1875 | | NASDAQ | 2000 | 30.0160 | 5.7500 |
|
| | | | DIVIDENDS: Common $0.01 par: None. | | | | | |
| | Annual Report |
|---|
| | | Income Statement | |
| 2009 | 2008 |
|---|
| REVENUES |
|
| | Net Sales | 22,023 | 23,993 | | EXPENSES |
|
| | Cost of Sales | (10,418) | (10,345) | | Selling, General and Administrative | (10,319) | (10,795) | | Research and Development | (3,182) | (2,465) | | Goodwill Impairment Charges | - | (638) | | Restructuring Charges | - | (118) | | Interest Income | 15 | 74 | | Other Income/expense | 3 | 12 | | Earnings before Taxes | (1,878) | (282) | | TAXES AND OTHER EXPENSES |
|
| | Provision for Income Tax | (42) | (213) | | Net Income (Loss) | (1,920) | (495) | | SUPPLEMENTARY INFO |
|
| | Gross Profit/loss | 11,605.00 | 13,648.00 | | Operating Income (Loss) | (1,896.00) | (368.00) | | Basic EPS - Continuing Operations | (0.04) | (0.01) | | Diluted EPS - Continuing Operations | (0.04) | (0.01) |
| | | | Balance Sheet | |
| 2009 | 2008 |
|---|
| CURRENT ASSETS |
|
| | Cash and Cash Equivalents | 5,642 | 4,771 | | Accounts Receivables | 4,522 | 5,385 | | Inventories | 3,552 | 4,775 | | Prepaid Expenses and Other Current Assets | 738 | 654 | | Total Current Assets | 14,454 | 15,585 | | NON CURRENT ASSETS |
|
| | Furniture, Fixtures and Leasehold Improvements | 3,834 | 3,920 | | Equipment | 9,972 | 10,059 | | Accumulated Depreciation | (12,839) | (12,781) | | Other Assets | 583 | 773 | | Total Assets | 16,004 | 17,556 | | CURRENT LIABILITIES |
|
| | Accounts Payable | 1,013 | 905 | | Accrued Expenses | 2,517 | 2,810 | | Accrued Compensation | 573 | 520 | | Total Current Liabilities | 4,103 | 4,235 | | NON CURRENT LIABILITIES |
|
| | Other Long-term Liabilities | 239 | 116 | | SHAREHOLDERS' EQUITY |
|
| | Common Stock - Par Value | 497 | 497 | | Additional Paid in Capital | 139,703 | 139,501 | | Accumulated Deficit | (130,183) | (128,263) | | Accumulated Other Comprehensive Income (Loss) | 1,645 | 1,470 | | Total Shareholders Equity | 11,662 | 13,205 | | Total Liabilities & Shareholders Equity | 16,004 | 17,556 |
| | | |
| | Interim Report
|
|---|
| | | Data Not Available | | | | | | | | | |
| | Pro Forma Report
|
|---|
| | | Data Not Available | | | | | | | | | |
| | Quarterly Report Information
|
|---|
| | | Quarterly Revenue, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | 5,440,000 | | 2009 |
1 | 4,990,000 | | 2009 |
2 | 5,470,000 | | 2009 |
3 | 5,050,000 | | 2009 |
4 | 6,510,000 | | 2009 |
Full Year
| 22,020,000 | | 2008 |
1 | 6,250,000 | | 2008 |
2 | 6,250,000 | | 2008 |
3 | 5,370,000 | | 2008 |
4 | 6,130,000 | | 2008 |
Full Year
| 23,990,000 | | 2007 |
1 | 5,220,000 | | 2007 |
2 | 6,220,000 | | 2007 |
3 | 5,150,000 | | 2007 |
4 | 6,530,000 | | 2007 |
Full Year
| 23,180,000 | | 2006 |
1 | 6,500,000 | | 2006 |
2 | 6,190,000 | | 2006 |
3 | 4,920,000 | | 2006 |
4 | 5,810,000 | | 2006 |
Full Year
| 23,420,000 | | 2005 |
1 | 6,930,000 | | 2005 |
2 | 6,890,000 | | 2005 |
3 | 6,660,000 | | 2005 |
4 | 5,350,000 | | 2005 |
Full Year
| 25,830,000 |
| | | | | | Quarterly Net Income, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | (320,000) | | 2009 |
1 | (950,000) | | 2009 |
2 | (730,000) | | 2009 |
3 | (370,000) | | 2009 |
4 | 130,000 | | 2009 |
Full Year
| (1,920,000) | | 2008 |
1 | 120,000 | | 2008 |
2 | 100,000 | | 2008 |
3 | (500,000) | | 2008 |
4 | (220,000) | | 2008 |
Full Year
| (500,000) | | 2007 |
1 | (1,270,000) | | 2007 |
2 | 230,000 | | 2007 |
3 | (1,350,000) | | 2007 |
4 | 210,000 | | 2007 |
Full Year
| (2,170,000) | | 2006 |
1 | (300,000) | | 2006 |
2 | (260,000) | | 2006 |
3 | (1,520,000) | | 2006 |
4 | (880,000) | | 2006 |
Full Year
| (2,960,000) | | 2005 |
1 | (2,160,000) | | 2005 |
2 | (470,000) | | 2005 |
3 | (530,000) | | 2005 |
4 | (1,820,000) | | 2005 |
Full Year
| (4,984,000) |
| | | | | | Quarterly EPS, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | (.01) | | 2009 |
1 | (.02) | | 2009 |
2 | (.01) | | 2009 |
3 | (.01) | | 2009 |
4 | Nil | | 2009 |
Full Year
| (.04) | | 2008 |
1 | Nil | | 2008 |
2 | Nil | | 2008 |
3 | (.01) | | 2008 |
4 | Nil | | 2008 |
Full Year
| (.01) | | 2007 |
1 | (.02) | | 2007 |
2 | Nil | | 2007 |
3 | (.03) | | 2007 |
4 | Nil | | 2007 |
Full Year
| (.04) | | 2006 |
1 | (.01) | | 2006 |
2 | (.01) | | 2006 |
3 | (.03) | | 2006 |
4 | (.02) | | 2006 |
Full Year
| (.06) | | 2005 |
1 | (.07) | | 2005 |
2 | (.01) | | 2005 |
3 | (.02) | | 2005 |
4 | (.04) | | 2005 |
Full Year
| (.14) |
| | | |
| |
|
